Honeywell Aerospace Inc.
HONAHoneywell Aerospace Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read deteriorating — profit −69.4% year on year, and 109% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Honeywell Aerospace Inc. trades at $164, between stages. It sits at 5% of a 52-week range of $158 to $268. On relative strength it has no relative-strength read yet.
Today the stock is between stages. At $164 it trades near its long-run average and sits at 5% of its 52-week range ($158–$268).
Against the market, two honest reads. Cumulative: over the last 4 months the stock moved −39% while the S&P 500 moved +2% — behind the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Honeywell Aerospace Inc. trades at 26.6× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 26.6× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Honeywell Aerospace Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 0 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The return-on-capital curve is not shown — net worth is negative, so a return on capital is not a meaningful number in any basis. This is a distressed balance sheet, and the stage is read from the growth curves alone.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +12.6% | — | — | — |
| Profit | −4.6% | — | — | — |
4-Factor Sector Score
42.9/100 — rank 29 of 30 in Aerospace & Defense · 48% evidence confidence · provisional, ranked below fully-evidenced peers
Honeywell Aerospace Inc. scores 42.9 out of 100 against the 30 companies it is compared with in Aerospace & Defense, ranking 29. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 7.3 + 15.6 + 10 + 10 = 42.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Honeywell Aerospace Inc. reported $4.5 B of revenue in the Jun 26 quarter, +5.4% year on year. That is the 6th straight quarter of year-on-year growth. Over 2 years it has compounded at 12.3% a year. The last full year, FY25, came in at $17.4 B. The last four reported quarters add to $17.9 B.
FY25 revenue came in at $17.4 B (+12.6% on the year), capping 2 years at 12.3% compound. The latest quarter (Jun 26) printed $4.5 B, +5.4% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +10.3% growth against the decade's 12.3% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Honeywell Aerospace Inc.'s operating margin is 12.8% in the Jun 26 quarter, −10.5 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 19.3% to 25.2%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 12.8%, −10.5 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 19.3%–25.2%.
🚨 Why the margin moved: operating margin went −10.5 pp year on year while gross margin went −1.4 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Honeywell Aerospace Inc. earned $0.3 B of net profit in the Jun 26 quarter, −69.4% year on year. Full-year FY25 profit was $2.7 B. The 2-year compound rate is −3.3%. That is 5.8% of the quarter's revenue. The same quarter a year earlier earned $0.8 B.
Jun 26 profit was $0.3 B, −69.4% year on year. On the full year, FY25 printed $2.7 B (−4.6%), and the 2-year compound rate is −3.3%.
🚨 Why profit moved: revenue contributed +5.4% and the margin −10.5 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −31.3% vs revenue +10.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 109% of Honeywell Aerospace Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $3.7 B of operating cash against $2.7 B of profit. After $0.5 B of capital spending, $3.2 B was left as free cash.
FY25: operating cash of $3.7 B against reported profit of $2.7 B, leaving free cash of $3.2 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 109% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Honeywell Aerospace Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 1.9% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Honeywell Aerospace Inc. earns a ROE of 32% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 15.6% net margin on 0.98× asset turns.
FY25 ROE is 32%.
Why the return is what it is — the wiring (FY25): 15.6% net margin × 0.98× asset turns × 2.08× balance-sheet leverage ≈ 31.8% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
Dividend
Honeywell Aerospace Inc. pays no dividend. Across the last 10 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Honeywell Aerospace Inc. does not currently pay a dividend. Across the last 10 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Honeywell Aerospace Inc.'s net worth is negative — it owes more than it owns — so a debt-to-equity ratio is not meaningful here. On the annual view that ratio went from 0.00 in FY24 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $15.8 B against shareholder equity of $−5.6 B — a debt-to-equity of −2.82. On the annual view, debt-to-equity went from 0.00 (FY24) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.5% of Honeywell Aerospace Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 1.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.5% of the float is sold short, and at typical trading volumes it would take about 1.0 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Honeywell Aerospace Inc.: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Lockheed Martin CorporationLMT | 72.1/100Favorable setup81% evidence | TURNING | 25.8/35 Revenue 7.2% · PAT 49.5% · OPM change 8.3 pp 83% evidence | 14.6/25 ROCE 6.8% · OPM 12.4% 76% evidence | 16.1/20 P/E 18.7× · PEG 0.35 65% evidence | 15.6/20 RS sector 5.3% · RS bench -9.6% · 1Y 12.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 25.8 + 14.6 + 16.1 + 15.6 = 72.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2RTX CorporationRTX | 65.6/100Favorable setup81% evidence | FADING | 21.7/35 Revenue 11.8% · PAT 26.1% · OPM change 1.2 pp 83% evidence | 15.3/25 ROCE 10.4% · OPM 12.7% 76% evidence | 12.1/20 P/E 33× · PEG 1.33 65% evidence | 16.5/20 RS sector 10% · RS bench -5.1% · 1Y 22.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 15.3 + 12.1 + 16.5 = 65.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Elbit Systems Ltd.ESLT | 60.8/100Mixed-positive evidence81% evidence | ASLEEP | 22.7/35 Revenue 13.7% · PAT 60.2% · OPM change 1.6 pp 83% evidence | 11.5/25 ROCE 3.1% · OPM 9.6% 76% evidence | 11.6/20 P/E 57.2× · PEG 1.13 65% evidence | 15.0/20 RS sector 13.9% · RS bench -2.2% · 1Y 52.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.7 + 11.5 + 11.6 + 15 = 60.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Howmet Aerospace Inc.HWM | 60.4/100Mixed-positive evidence81% evidence | ASLEEP | 24.9/35 Revenue 18.1% · PAT 33.9% · OPM change 2.5 pp 83% evidence | 16.3/25 ROCE 7% · OPM 27.9% 76% evidence | 8.9/20 P/E 57.9× · PEG 1.62 65% evidence | 10.3/20 RS sector 4.3% · RS bench -9.9% · 1Y 20.7%3 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 16.3 + 8.9 + 10.3 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5HEICO CorporationHEI | 60.4/100Mixed-positive evidence81% evidence | ASLEEP | 24.6/35 Revenue 18.8% · PAT 30.2% · OPM change 2.9 pp 83% evidence | 14.4/25 ROCE 4.3% · OPM 25.5% 76% evidence | 10.3/20 P/E 48.2× · PEG 1.56 65% evidence | 11.1/20 RS sector -0.4% · RS bench -13.9% · 1Y -6.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 14.4 + 10.3 + 11.1 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Embraer S.A.EMBJ | 58.4/100Mixed-positive evidence66% evidence | BREAKING OUT | 16.6/35 Revenue 20% · PAT -22.2% · OPM change 1 pp 53% evidence | 7.7/25 ROCE 1.1% · OPM 5.6% 57% evidence | 14.1/20 P/E 54.9× · PEG 0.51 65% evidence | 20.0/20 RS sector 23.6% · RS bench 6.8% · 1Y 29.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 7.7 + 14.1 + 20 = 58.4 · Decision use: Price leads the evidence: RS versus the benchmark is 6.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7General Dynamics CorporationGD | 56.1/100Thin evidence · provisional58% evidence | ASLEEP | 16.9/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 12.3/25 ROCE 3.7% · OPM 10.4% 76% evidence | 11.0/20 P/E 22.8× · PEG — 15% evidence | 15.9/20 RS sector 7.4% · RS bench -7.1% · 1Y 8.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 12.3 + 11 + 15.9 = 56.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8GE AerospaceGE | 55.3/100Mixed-positive evidence81% evidence | ASLEEP | 19.5/35 Revenue 21.7% · PAT 16.2% · OPM change -0.3 pp 83% evidence | 16.4/25 ROCE 11.7% · OPM 20.6% 76% evidence | 7.2/20 P/E 43.5× · PEG 2.38 65% evidence | 12.2/20 RS sector 6.1% · RS bench -8.3% · 1Y 4.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 16.4 + 7.2 + 12.2 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Hexcel CorporationHXL | 54.0/100Thin evidence · provisional56% evidence | FADING | 20.8/35 Revenue — · PAT — · OPM change 1.8 pp 39% evidence | 10.6/25 ROCE 2.9% · OPM 11.5% 76% evidence | 9.9/20 P/E 50.3× · PEG — 15% evidence | 12.7/20 RS sector 11.4% · RS bench -3.7% · 1Y 42.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 10.6 + 9.9 + 12.7 = 54 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Curtiss-Wright CorporationCW | 53.3/100Mixed-positive evidence81% evidence | ASLEEP | 21.9/35 Revenue 10.5% · PAT 20% · OPM change 1.5 pp 83% evidence | 19.6/25 ROCE 17.4% · OPM 19.4% 76% evidence | 7.3/20 P/E 51.7× · PEG 2.28 65% evidence | 4.5/20 RS sector -5.9% · RS bench -19% · 1Y 10.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 19.6 + 7.3 + 4.5 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Woodward, Inc.WWD | 52.8/100Thin evidence · provisional56% evidence | ASLEEP | 20.3/35 Revenue — · PAT — · OPM change 1.2 pp 39% evidence | 14.1/25 ROCE 4.9% · OPM 14.7% 76% evidence | 9.8/20 P/E 50.5× · PEG — 15% evidence | 8.6/20 RS sector 1.6% · RS bench -12.5% · 1Y 35.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 14.1 + 9.8 + 8.6 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Leonardo DRS, Inc.DRS | 49.9/100Thin evidence · provisional56% evidence | ASLEEP | 20.3/35 Revenue — · PAT — · OPM change 1.7 pp 39% evidence | 11.6/25 ROCE 3.3% · OPM 9.1% 76% evidence | 10.7/20 P/E 35.9× · PEG — 15% evidence | 7.3/20 RS sector -3% · RS bench -16.5% · 1Y -10.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 11.6 + 10.7 + 7.3 = 49.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Textron Inc.TXT | 45.6/100Thin evidence · provisional56% evidence | ASLEEP | 15.9/35 Revenue — · PAT — · OPM change -0.8 pp 39% evidence | 9.1/25 ROCE 2% · OPM 6.3% 76% evidence | 11.3/20 P/E 17.4× · PEG — 15% evidence | 9.3/20 RS sector -3.4% · RS bench -16.8% · 1Y -4.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 9.1 + 11.3 + 9.3 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Northrop Grumman CorporationNOC | 45.5/100Mixed-negative evidence81% evidence | BASING | 10.3/35 Revenue 5.9% · PAT 14% · OPM change -3.7 pp 83% evidence | 10.6/25 ROCE 3% · OPM 10.1% 76% evidence | 14.5/20 P/E 16.2× · PEG 1.01 65% evidence | 10.1/20 RS sector -5.4% · RS bench -18.8% · 1Y -8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 10.6 + 14.5 + 10.1 = 45.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15The Boeing CompanyBA | 44.0/100Mixed-negative evidence64% evidence | ASLEEP | 19.9/35 Revenue 24.8% · PAT — · OPM change 1.4 pp 62% evidence | 4.2/25 ROCE 0.3% · OPM 0.6% 76% evidence | 9.0/20 P/E 93.7× · PEG — 15% evidence | 10.9/20 RS sector -2.3% · RS bench -15.8% · 1Y -8.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 4.2 + 9 + 10.9 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16CAE Inc.CAE | 43.9/100Mixed-negative evidence66% evidence | ASLEEP | 10.8/35 Revenue 4.4% · PAT -22.4% · OPM change -7.6 pp 53% evidence | 10.6/25 ROCE 2% · OPM 12.9% 57% evidence | 14.7/20 P/E 37.3× · PEG 0.68 65% evidence | 7.8/20 RS sector -7.6% · RS bench -20.5% · 1Y -15.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 10.6 + 14.7 + 7.8 = 43.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 17Huntington Ingalls Industries, Inc.HII | 43.4/100Thin evidence · provisional56% evidence | BASING | 16.5/35 Revenue — · PAT — · OPM change -0.9 pp 39% evidence | 9.1/25 ROCE 2.2% · OPM 5% 76% evidence | 11.4/20 P/E 16.7× · PEG — 15% evidence | 6.4/20 RS sector -12.8% · RS bench -25.3% · 1Y -0.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 9.1 + 11.4 + 6.4 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Axon Enterprise, Inc.AXON | 43.0/100Mixed-negative evidence71% evidence | FADING | 20.0/35 Revenue 34.6% · PAT -39% · OPM change 5.4 pp 83% evidence | 6.4/25 ROCE 0.9% · OPM 5.2% 76% evidence | 8.6/20 P/E 232.6× · PEG — 15% evidence | 8.0/20 RS sector -9.7% · RS bench -21.8% · 1Y -42.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 6.4 + 8.6 + 8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19TransDigm Group IncorporatedTDG | 42.6/100Mixed-negative evidence81% evidence | ASLEEP | 15.5/35 Revenue 16.6% · PAT 10.3% · OPM change -1.6 pp 83% evidence | 15.9/25 ROCE 5.5% · OPM 44.8% 76% evidence | 5.3/20 P/E 40.2× · PEG 4.28 65% evidence | 5.9/20 RS sector -8.3% · RS bench -20.9% · 1Y -15.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 15.9 + 5.3 + 5.9 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20StandardAero, Inc.SARO | 41.9/100Thin evidence · provisional56% evidence | ASLEEP | 18.4/35 Revenue 15% · PAT 100% · OPM change -0.2 pp 53% evidence | 9.1/25 ROCE 2.8% · OPM 8.8% 57% evidence | 10.9/20 P/E 29.4× · PEG — 15% evidence | 3.5/20 RS sector -13% · RS bench -25.1% · 1Y -19.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 9.1 + 10.9 + 3.5 = 41.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Rocket Lab CorporationRKLB | 41.8/100Mixed-negative evidence61% evidence | ASLEEP | 25.2/35 Revenue 52.6% · PAT — · OPM change 16.7 pp 62% evidence | 3.2/25 ROCE -2.4% · OPM -24.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.4/20 RS sector -7.4% · RS bench -20.2% · 1Y 35.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.2 + 3.2 + 10 + 3.4 = 41.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.4% and the one-year return is 35.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 22L3Harris Technologies, Inc.LHX | 39.7/100Thin evidence · provisional58% evidence | ASLEEP | 17.3/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 10.0/25 ROCE 1.9% · OPM 11.1% 76% evidence | 8.9/20 P/E 96× · PEG — 15% evidence | 3.5/20 RS sector -13.5% · RS bench -25.8% · 1Y -12.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 10 + 8.9 + 3.5 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23FTAI Aviation Ltd.FTAI | 39.0/100Thin evidence · provisional56% evidence | ASLEEP | 12.9/35 Revenue — · PAT — · OPM change -9.6 pp 39% evidence | 13.3/25 ROCE 5% · OPM 20.5% 76% evidence | 9.1/20 P/E 58.8× · PEG — 15% evidence | 3.7/20 RS sector -6.9% · RS bench -20.3% · 1Y 6.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 13.3 + 9.1 + 3.7 = 39 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24AeroVironment, Inc.AVAV | 38.0/100Mixed-negative evidence71% evidence | BASING | 17.6/35 Revenue 100% · PAT -702.3% · OPM change 3.9 pp 83% evidence | 6.1/25 ROCE 1.8% · OPM 8.9% 76% evidence | 8.7/20 P/E 97.8× · PEG — 15% evidence | 5.6/20 RS sector -26.3% · RS bench -36.7% · 1Y -42.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 6.1 + 8.7 + 5.6 = 38 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Kratos Defense & Security Solutions, Inc.KTOS | 37.8/100Thin evidence · provisional56% evidence | ASLEEP | 18.4/35 Revenue 21.9% · PAT 50% · OPM change -0.9 pp 53% evidence | 6.5/25 ROCE 0.2% · OPM 1.3% 57% evidence | 8.5/20 P/E 423.2× · PEG — 15% evidence | 4.4/20 RS sector -29.8% · RS bench -40.1% · 1Y -41.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 6.5 + 8.5 + 4.4 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26BWX Technologies, Inc.BWXT | 34.4/100Adverse evidence66% evidence | ASLEEP | 16.7/35 Revenue 21.4% · PAT 19% · OPM change -1.8 pp 53% evidence | 11.1/25 ROCE 2.7% · OPM 9.9% 57% evidence | 5.2/20 P/E 54.7× · PEG 2.86 65% evidence | 1.4/20 RS sector -17% · RS bench -28.7% · 1Y -15.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 11.1 + 5.2 + 1.4 = 34.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Moog Inc.MOG-B | 52.9/100Thin evidence · provisional33% evidence | FADING | 19.5/35 Revenue — · PAT — · OPM change 1 pp 32% evidence | 12.9/25 ROCE 4.4% · OPM 10.8% 76% evidence | 10.5/20 P/E 36.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y 84.3%9 of 11 weeks ahead 0% evidence |
| Exact sum: 19.5 + 12.9 + 10.5 + 10 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28DPC Holdings PLCDPC | 46.9/100Thin evidence · provisional16% evidence | 16.5/35 Revenue — · PAT — · OPM change — 6% evidence | 10.4/25 ROCE 5.3% · OPM 8.4% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.5 + 10.4 + 10 + 10 = 46.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Honeywell Aerospace Inc.this pageHONA | 42.9/100Thin evidence · provisional48% evidence | ASLEEP | 7.3/35 Revenue 10.1% · PAT -32.7% · OPM change -10.5 pp 83% evidence | 15.6/25 ROCE 8.9% · OPM 12.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 1 week ahead 0% evidence |
| Exact sum: 7.3 + 15.6 + 10 + 10 = 42.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Space Exploration Technologies Corp.SPCX | 40.0/100Thin evidence · provisional33% evidence | ASLEEP | 16.6/35 Revenue — · PAT — · OPM change 17.2 pp 39% evidence | 3.4/25 ROCE -1.6% · OPM -1.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 1 week ahead 0% evidence |
| Exact sum: 16.6 + 3.4 + 10 + 10 = 40 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Honeywell Aerospace Inc.'s stock price today?
Honeywell Aerospace Inc. trades at $164. The company is valued at $52.0 B. The stock sits at 5% of its 52-week range of $158–$268. — as of 19 September 2026.
What were Honeywell Aerospace Inc.'s latest quarterly results?
Honeywell Aerospace Inc. reported revenue of $4.5 B and net profit of $0.3 B for the Jun 26 quarter. Revenue rose 5.4% and profit fell 69.4% year on year. Earnings per share were $0.78. The operating margin was 12.8%, 10.5 pp lower than a year earlier. — as of 19 September 2026.
What is Honeywell Aerospace Inc.'s revenue?
Honeywell Aerospace Inc. reported revenue of $4.5 B in the Jun 26 quarter, +5.4% year on year. For the full FY25 fiscal year, revenue was $17.4 B (+12.6%). Over the last 2 years revenue compounded at 12.3% a year. — as of 19 September 2026.
What is Honeywell Aerospace Inc.'s profit?
Honeywell Aerospace Inc. earned $0.3 B of net profit in the Jun 26 quarter, −69.4% year on year. Full-year FY25 profit was $2.7 B. The operating margin ran 12.8% in the latest quarter. — as of 19 September 2026.
What is Honeywell Aerospace Inc.'s market cap?
Honeywell Aerospace Inc.'s market capitalisation is $52.0 B at a stock price of $164. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 19 September 2026.
Does Honeywell Aerospace Inc. pay a dividend?
No — Honeywell Aerospace Inc. has declared no dividend per share in any of its last 10 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 19 September 2026.
Is Honeywell Aerospace Inc. growing?
Not right now — Honeywell Aerospace Inc.'s latest numbers are shrinking: latest-quarter revenue +5.4% year on year, profit −69.4%, and the margin −10.5 pp at 12.8%. The 2-year compound rates are 12.3% (revenue) and −3.3% (profit). The earnings engine currently reads: deteriorating — as of 19 September 2026.
How is Honeywell Aerospace Inc. performing?
Honeywell Aerospace Inc.'s latest readings are below. Its latest quarter's revenue rose 5.4% and profit fell 69.4% year on year. This describes what the data did, not a rating. — as of 19 September 2026.
Will Honeywell Aerospace Inc.'s stock price go up?
This page publishes no price forecast for Honeywell Aerospace Inc. What it measures instead: the stock price is $164. Direction is not something this site claims to know. — as of 19 September 2026.
Is the market betting against Honeywell Aerospace Inc.?
No — short interest is 1.5% of Honeywell Aerospace Inc.'s tradable float, about 1.0 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 19 September 2026.
What is Honeywell Aerospace Inc.'s capex?
Honeywell Aerospace Inc. spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 19 September 2026.
What is Honeywell Aerospace Inc.'s cash flow?
Honeywell Aerospace Inc. generated $3.7 B of operating cash flow in FY25 and $3.2 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $2.7 B, so operating cash ran ahead of profit. — as of 19 September 2026.
Is Honeywell Aerospace Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 109% of Honeywell Aerospace Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $3.7 B against reported profit of $2.7 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 19 September 2026.
Where is Honeywell Aerospace Inc. in its business cycle?
Honeywell Aerospace Inc.'s FY25 operating margin was 19.3%, against a 3-year band of 19.3%–25.2%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 12.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 19 September 2026.
What could break the Honeywell Aerospace Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 19 September 2026.
Is Honeywell Aerospace Inc. a stock worth studying right now?
This is not investment advice. The machine read: Honeywell Aerospace Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 19 September 2026.
Not SEBI Registered !! Not Investment advice !!